Myasthenia gravis is a well-treatable disease, in which a prompt diagnosis and an adequate management can achieve satisfactory control of symptoms in the great majority of patients. Improved knowledge of the disease pathogenesis has led to recognition of patient subgroups, according to associated antibodies, age at onset and thymus pathology, and to a more personalized treatment. When myasthenia gravis is suspected on clinical grounds, diagnostic confirmation relies mainly on the detection of specific antibodies. Neurophysiological studies and, to a lesser extent, clinical response to cholinesterase inhibitors support the diagnosis in seronegative patients. In these cases, the differentiation from congenital myasthenia can be challenging. Treatment planning must consider weakness extension and severity, disease subtype, thymus pathology, together with patient characteristics and comorbidities. Since most subjects with myasthenia gravis require long-term immunosuppressive therapy, surveillance of expected and potential adverse events is critical. For patients refractory to conventional immunosuppression, the use of biologic agents is highly promising. These recommendations are addressed to non-experts on neuromuscular transmission disorders. The diagnostic procedures and therapeutic approaches hereafter described are largely accessible in Italy.

Italian recommendations for the diagnosis and treatment of myasthenia gravis / Evoli, A; Antonini, G; Antozzi, C; Dimuzio, A; Habetswallner, F; Iani, C; Inghilleri, M; Liguori, R; Mantegazza, R; Massa, R; Pegoraro, E; Ricciardi, R; Rodolico, C.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - (2019), pp. 1-14. [10.1007/s10072-019-03746-1]

Italian recommendations for the diagnosis and treatment of myasthenia gravis

Antonini G
Secondo
Membro del Collaboration Group
;
Inghilleri M
Membro del Collaboration Group
;
2019

Abstract

Myasthenia gravis is a well-treatable disease, in which a prompt diagnosis and an adequate management can achieve satisfactory control of symptoms in the great majority of patients. Improved knowledge of the disease pathogenesis has led to recognition of patient subgroups, according to associated antibodies, age at onset and thymus pathology, and to a more personalized treatment. When myasthenia gravis is suspected on clinical grounds, diagnostic confirmation relies mainly on the detection of specific antibodies. Neurophysiological studies and, to a lesser extent, clinical response to cholinesterase inhibitors support the diagnosis in seronegative patients. In these cases, the differentiation from congenital myasthenia can be challenging. Treatment planning must consider weakness extension and severity, disease subtype, thymus pathology, together with patient characteristics and comorbidities. Since most subjects with myasthenia gravis require long-term immunosuppressive therapy, surveillance of expected and potential adverse events is critical. For patients refractory to conventional immunosuppression, the use of biologic agents is highly promising. These recommendations are addressed to non-experts on neuromuscular transmission disorders. The diagnostic procedures and therapeutic approaches hereafter described are largely accessible in Italy.
2019
myasthenia gravis; thymectomy; Immunosuppressive therapy; plasma exchange; rituximab
01 Pubblicazione su rivista::01a Articolo in rivista
Italian recommendations for the diagnosis and treatment of myasthenia gravis / Evoli, A; Antonini, G; Antozzi, C; Dimuzio, A; Habetswallner, F; Iani, C; Inghilleri, M; Liguori, R; Mantegazza, R; Massa, R; Pegoraro, E; Ricciardi, R; Rodolico, C.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - (2019), pp. 1-14. [10.1007/s10072-019-03746-1]
File allegati a questo prodotto
File Dimensione Formato  
Evoli_Italian_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 798.35 kB
Formato Adobe PDF
798.35 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1235996
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 32
social impact